6709.TWO Advagene Biopharma Co. Ltd.
- Market cap
- TWD 1.44B
- P/E
- -
- P/B
- 4.33x
- ROE
- -44.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6709.TWO undervalued?
Graham numberThe Graham number of Advagene Biopharma Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Advagene Biopharma Co. Ltd. fundamental analysis
No fundamental analysis for Advagene Biopharma Co. Ltd. yet.
Advagene Biopharma Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Advagene Biopharma Co. Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.
Full company profileAdvagene Biopharma Co. Ltd. financial statements
Advagene Biopharma Co. Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Operating Income | -149M | -126M | -98.8M | -70.1M | -92.6M | -118M | -92.1M | -70.8M | -70.9M |
| EBITDA | -146M | -121M | -94.3M | -62.2M | -84.8M | -107M | -80.1M | -67.1M | -65.9M |
| Net Income | -138M | -111M | -91.6M | -70.2M | -92.7M | -118M | -92.1M | -69.4M | -68.3M |
| EPS | -3.11 | -2.51 | -2.05 | -1.57 | -1.88 | -2.40 | -1.83 | -1.16 | -1.14 |
| Balance Sheet | |||||||||
| Total Assets | 226M | 359M | 279M | 316M | 260M | 141M | 148M | 232M | 167M |
| Total Liabilities | 12.5M | 11.9M | 7.85M | 16.9M | 10.8M | 9.08M | 7.97M | 11.7M | 14.3M |
| Shareholders' Equity | 214M | 347M | 271M | 299M | 250M | 132M | 140M | 221M | 152M |
| Cash & Short-term Investments | 18.6M | 13.5M | 238M | 273M | 224M | 103M | 125M | 52.8M | 55.3M |
| Total Debt | - | - | - | 6.19M | 4.40M | 2.57M | 870K | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -177M | -39.5M | -35.7K | -30.9M | -67.2M | -109M | -77.7M | -70.6M | -63.3M |
| Capital Expenditure | 544K | 342K | 6.04M | 627K | 521K | 10.2M | 0.00 | 476K | 2.31M |
| Free Cash Flow | -186M | -39.8M | -6.07M | -31.5M | -67.7M | -120M | -77.7M | -71.1M | -65.6M |
| Ratios | |||||||||
| ROE | -64.6% | -32.1% | -33.8% | -23.4% | -37.1% | -89.8% | -65.8% | -31.5% | -44.9% |
| ROA | -61.1% | -31.0% | -32.8% | -22.2% | -35.6% | -84.1% | -62.3% | -29.9% | -41.0% |
| Debt to Equity | - | - | - | 0.02x | 0.02x | 0.02x | 0.01x | - | - |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Advagene Biopharma Co. Ltd. dividends
Advagene Biopharma Co. Ltd. has not paid dividends in the last 9 fiscal years.
Last stock split: 3457:3426 on Aug 2, 2023.
Who owns Advagene Biopharma Co. Ltd.
Ownership data of Advagene Biopharma Co. Ltd. is not available yet.
Advagene Biopharma Co. Ltd. company profile
- Company name
- Advagene Biopharma Co. Ltd.
- Ticker
- 6709.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- No.308, Neihu Road, Taipei, Taiwan, 114
- Phone
- 886 2 2797 0073
- Website
- advagene.com.tw
About Advagene Biopharma Co. Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.
Advagene Biopharma Co. Ltd. management
6- Mr. Yu-Shen HsuPresident, GM & Director
- Mr. Chen BryonFounder & Director
- Eric ChenChief Financial Officer
- Kuangdun SuAccounting Supervisor
- Frank HsiaoExecutive Vice President
- Pongo PengExecutive Vice President